Eric Gornstein spends his days on a problem most executives never face: how do you sell a test that has no rival because it did not exist before? As Chief Executive Officer of Pearl Diagnostics, a small company spun out of Johns Hopkins, he is steering a product that just cleared the U.S. Food and Drug Administration - MycoMEIA, the first non-invasive urine assay cleared to help detect invasive aspergillosis, a serious fungal lung infection.
The company is tiny by biopharma standards, roughly five employees on the books, working out of a lab on Ashland Avenue in East Baltimore near the Hopkins medical campus. What it lacks in headcount it makes up for in a rare fact: it has an actual, cleared product. Few companies at Pearl's stage ever get one to market. Gornstein's job is to make sure it gets used.
FDA clearance is the finish line for a research lab. For a company, it is the starting gun.
That framing captures why Pearl brought him in. Gornstein joined in the fall of 2025, initially to help with commercialization, then stepped into the top job. His arrival marks a deliberate handoff - from an inventor-founder who proved the science to an operator whose entire career has been about the messier second half: getting a proven technology onto hospital order sheets and into clinical routine.
A career built in the gap between science and market
Gornstein describes himself as an entrepreneurial biopharmaceutical executive, and the resume backs it up. Over more than two decades he has worked across corporate, portfolio, and product strategy at every phase of research and development, spanning therapeutic areas as varied as autoimmune disease, hematology and oncology, the central nervous system, cardiovascular, and endocrine conditions. He has worked with small molecules, biologics, peptides, oligonucleotides, and cell and gene therapies - a range that is unusual even among seasoned operators.
He has also been a dealmaker. Gornstein has sat on both buy-side and sell-side teams, structuring, negotiating, and executing transactions with large global companies. That mix of strategy and negotiation is the throughline of his work: he is the person who translates a promising asset into a business other people are willing to pay for.
The clearest example came at Radius Health, where he led the company's commercial insights and analytics function and helped build out the commercial operations organization to launch its first product, Tymlos, in the United States. Standing up the infrastructure behind a first launch is unglamorous, foundational work - the kind that decides whether a good drug reaches patients or stalls. More recently he served as Senior Vice President of Business Development and Cell Therapy Partnerships at bit.bio, and he held a strategy role at Talaris Therapeutics. He holds an Executive MBA from MIT's Sloan School of Management.
The best commercial leaders are the ones who quietly turn a breakthrough into a purchase order.
Why a big-pharma dealmaker joined a five-person startup
On paper, the move looks like a step down in scale. Gornstein went from large organizations and a blockbuster launch to a company you could fit around a conference table. The logic is in one word that appears again and again in Pearl's story: non-invasive.
Invasive aspergillosis is dangerous and hard to catch early. It strikes people whose defenses are down - cancer patients, transplant recipients, and others with severe lung disease. Confirming it has traditionally meant difficult procedures and imperfect tests. Pearl's assay works from a urine sample, something that can be collected in a cup. If it performs in the field the way it did in validation, it offers clinicians an earlier, easier read on a condition where time matters. For an executive who has built his career on getting real innovation to patients faster, a proven technology that only needed a market was a compelling bet.
MycoMEIA Aspergillus
A microplate-based ELISA that detects invasive aspergillosis from a urine sample. Cleared by the FDA in August 2025 through the 510(k) pathway, and CE marked for sale across the European Union. It is the first non-invasive urine-based diagnostic of its kind to reach the U.S. market.
The $11.2 million question
In 2026, Pearl Diagnostics closed an $11.2 million Series A - a meaningful raise for a company its size, and a vote of confidence in its unusually advanced position. The plan for the money is straightforward and squarely in Gornstein's wheelhouse: market the product in the United States and expand into Europe, where the company already holds a CE mark that clears the way for sales across the EU. Total funding to date sits north of $18 million.
Building a market for a first-of-its-kind test is a specific kind of hard. There is no incumbent to displace and no established buying pattern to plug into, which means the work is as much education as it is sales - showing clinicians and laboratories why a new category belongs in their routine. It is exactly the problem Gornstein has spent a career learning to solve, now compressed into a startup where the outcome rests largely on his execution.
The handoff and the horizon
Pearl Diagnostics was founded by Dr. Kieren Marr, a professor of medicine, oncology, and business at Johns Hopkins who spent years developing the underlying technology before turning entrepreneur. The company remains a woman-owned small business, with Marr as founder, president, and board chair. Gornstein's appointment as CEO is the classic and often tricky moment when a research-driven venture brings in a commercial leader to scale what the science made possible.
What comes next is a test of that transition. A cleared product, cash in the bank, a European door already open, and a category with no direct competitor - the pieces are in place. Whether they add up to a business that lasts depends on the second half of the story, the part that begins after the science is done. That is the half Gornstein has spent 25 years living in, and the reason he took the job.
The hardest part of medtech is not the invention. It is the market.